Who Paid My Doc
Dextenza
Drug Corticosteroid Intracanalicular Insert
NDC 70382-204-99
General payments
$2,026,367
Research payments
$7,116,125
Through program year 2025, $2,026,367 in general payments and $7,116,125 in research payments were reported against Dextenza (Corticosteroid Intracanalicular Insert).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
11 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $200,539 | 3,449 |
| 2024 | General | $263,528 | 3,749 |
| 2024 | Research | $495,335 | 44 |
| 2023 | General | $209,864 | 3,526 |
| 2023 | Research | $930,869 | 76 |
| 2022 | General | $149,285 | 1,754 |
| 2022 | Research | $1,766,451 | 127 |
| 2021 | General | $349,170 | 1,871 |
| 2021 | Research | $1,875,441 | 159 |
| 2020 | General | $853,981 | 1,207 |
| 2020 | Research | $2,048,028 | 165 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 19 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 44 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
15,556 general · 571 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.